Abstract library

8 results for "Marmissolle".
#444 Gallium 68 DOTATATE PET CT Assessment of Patients (pts.) with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs): First Experience in a Multidisciplinary Team in Argentina (Argentum Group)
Introduction: 68Ga-DOTATATE PET CT offers higher resolution than other scintigraphic techniques in terms of localization of the primary tumor and staging of GEP NETs. Different reports in the literature suggest increased sensitivity but clear consensus about indication in neuroendocrine tumors is unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Juan O'Connor
Authors: Eleta M, Pesce V, Bestani C, O'Connor J, ...
#702 Observational Study of Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors in Argentina: Results from the Large Database of a Multidisciplinary Group. Clinical Multicenter Study
Introduction: Neuroendocrine tumors (NETs) consist of a spectrum of malignancies that can arise from neuroendocrine cells throughout the body.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Juan Manuel O'Connor
#868 Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Claudia Bestani
#938 Clinical Characteristics of 144 patients (pts) Included in a Multidisciplinary Group, with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) G2 (WHO 2010). Grupo Argentum.
Introduction: Neuroendocrine tumors (NETs) G2 of the digestive tract are a heterogeneous group of tumors. Several treatment options including chemotherapy and target therapy are used, but there is a lack of prospective trials assessing the role of predictive factors in this population.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Juan Manuel O'Connor
#1025 Evaluation of Patients (pts) with Neuroendocrine Tumors at First Cardiological Consultation with Echocardiographic (Echo) Method. Argentum Group
Introduction: The incidence of carcinoid tumors is approximately 1 in 75,000 of the population of whom 50% develop carcinoid syndrome. Once carcinoid syndrome has developed, approximately 50% of these patients develop carcinoid heart disease which typically causes abnormalities in the right side of the heart.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: MD Daniel Santos
#1147 Correlation of Serum Plasma Chromogranin A with Survival and Disease Features in Patients with Gastroenteropancreatic Neuroendocrine Tumors. First Results in a Large Database in Argentina. ARGENTUM GROUP.
Introduction: The plasma chromogranin A (CgA) is the best general biomarker in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). CrA levels are elevated in a variety of GEP-NETs and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in this population.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Juan Manuel O'Connor
Authors: Belli S, O'Connor J M, Oneto A, Pesce V, ...
#1157 Cardiac Evaluation as Part of the Initial Extension Studies in Neuroendocrine Tumors. Experience in a Multidisciplinary Team. ARGENTUM GROUP
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine tumors and is screened for using echocardiography. Published case series showed that when cardiological evaluation is done at least 50% of the patients have CHD, and 33% had surgical indication.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
#1848 Liver Metastatic Disease (LMD) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Incidence, Treatment and Survival in a Multicenter Study in Argentina. Preliminary Report. ARGENTUM GROUP
Introduction: The first observational Study from our Group in Argentina, showed 60% incidence of liver mets at initial diagnosis. The treatment encompasses a wide scope of surgical and non-surgical modalities.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
Keywords: Liver, NETs